The latest news, announcements and press releases from Terray Therapeutics.
BOSTON and LOS ANGELES - October 28, 2024 — Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, and Terray Therapeutics, Inc., a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced today that they have entered into a strategic collaboration to jointly discover and develop small molecule medicines against transcription factor targets of interest. The collaboration combines Odyssey’s expertise in immunology and transcription factor biology with Terray’s complementary expertise in immunology and integrated AI platform, tNova, which leverages proprietary experimental data at scale to power its AI capabilities. Together, the companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across inflammatory diseases.
This is the News section of the company profile page for Terray Therapeutics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
